For our Spotlight on biomarker discovery and development we carried out a survey to gain insights into biomarkers used, their challenges and future outlook.
New research has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy.
A combination of CBL0137 and panobinostat has been demonstrated to effectively treat neuroblastoma in mice. This combination therapy has the potential to lead the fight against this aggressive childhood cancer.
From novel biomarkers, to the potential use of the Zika virus as a tumor treatment, read our round-up of the biggest neuro-oncology news from the last year as we mark World Cancer Day.
Prognostic value of pre- and post-treatment health-related quality of life in predicting survival of patients with brain metastases
The present study explores the prognostic survival value of pretreatment health-related quality of life (HRQOL) and changes in HRQOL following whole-brain radiation treatment in patients with brain metastases.
Researchers have uncovered the role of cellular prion protein (PrPC) in Neurofibromatosis Type 2 (NF2) related tumors, offering hope to neuro-tumor patients.
A new assay test for five cancer-associated genes with the goal of aiding prediction of neuroblastoma in children has been reported.
New research from the University of Edinburgh highlights how an olive oil component, oleic acid, inhibits cancer-causing proteins in the brain.
A large, multicenter, genome-wide association study has identified a number of new genetic risk loci for malignant brain tumors.
Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.